A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
PHASE3CompletedINTERVENTIONAL
Enrollment
314
Participants
Timeline
Start Date
October 31, 2001
Study Completion Date
March 31, 2005
Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG
risperidone
All Listed Sponsors
lead
Janssen, LP
INDUSTRY
NCT00495118 - A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients. | Biotech Hunter | Biotech Hunter